Veradermics (MANE) Cash from Financing Activities (2025 - 2026)
Veradermics' (MANE) quarterly Cash from Financing Activities came in at $269.1 million in Q1 2026, up 3094.98% YoY from $8.4 million in Q1 2025, and up 3094.98% on a QoQ basis from $8.4 million in Q1 2025.
Powered by 
Analysis
Veradermics (MANE) Cash from Financing Activities (2025 - 2026) Analysis & Trends
Veradermics (MANE) has 2 years of Cash from Financing Activities data on file, last reported at $269.1 million in Q1 2026.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Financing Activities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | -426.70 Mn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | -1.22 Bn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | 14.00 Mn |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | 2.42 Bn |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | -6.05 Mn |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | 36.24 Mn |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | -273.15 Mn |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | 27.18 Mn |
| 10 | Veradermics | 3.96 Bn | 3.96 Bn | - | 442.70 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 442.70 Mn |
| Mar 31, 2026 | 269.11 Mn |
| Jun 30, 2025 | 129,000.00 |
| Mar 31, 2025 | 8.42 Mn |